Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.

Enliven Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

CUMULATIVE MAJOR MOLECULAR RESPONSE (MMR) RATE OF 69% BY 24 WEEKS, WITH 53% OF PATIENTS ACHIEVING MMR BY 24 WEEKS IN ONGOING RANDOMIZED PHASE 1B COHORTS ELVN-001 CONTINUES TO DEMONSTRATE A FAVORABLE SAFETY AND TOLERABILITY PROFILE ACROSS ALL DOSE LEVELS EVALUATED, CONSISTENT WITH PREVIOUSLY REPORTED DATA DATA FURTHER REINFORCE ELVN-001'S POSITIONING AS THE POTENTIALLY BEST-IN-CLASS ACTIVE-SITE TKI IN CML MULTIPLE KEY DATA, REGULATORY AND OPERATIONAL CATALYSTS EXPECTED IN 2026 BOULDER, COLO., JAN. 8, 2026 /PRNEWSWIRE/ --ENLIVEN THERAPEUTICS, INC. (ENLIVEN OR THE COMPANY) (NASDAQ: ELVN), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF SMALL MOLECULE THERAPEUTICS, TODAY ANNOUNCED POSITIVE INITIAL DATA FROM THE ONGOING PHASE 1B ENABLE CLINICAL TRIAL EVALUATING ELVN-001 IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) THAT IS RELAPSED, REFRACTORY OR INTOLERANT TO AVAILABLE TYROSINE KINASE INHIBITORS (TKIS) (NCT05304377).

ENLIVEN REPORTS POSITIVE INITIAL PHASE 1B DATA FOR ELVN-001 IN CML AND OUTLINES 2026 CLINICAL MILESTONES

SCOTT GARLAND, A SEASONED BIOPHARMA EXECUTIVE WITH A STRONG TRACK RECORD OF LEADING SUCCESSFUL COMPANIES AND DRUG LAUNCHES, JOINS ENLIVEN'S BOARD OF DIRECTORS BUILDING ON POSITIVE DATA REPORTED IN 2025, ENLIVEN CONTINUES TO PREPARE FOR PHASE 3 TRIAL INITIATION IN 2026 AND THE COMMERCIALIZATION OF ELVN-001 BOULDER,COLO., JAN. 7, 2026 /PRNEWSWIRE/ --ENLIVEN THERAPEUTICS, INC. (ENLIVEN OR THE COMPANY) (NASDAQ: ELVN), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF SMALL MOLECULE THERAPEUTICS, TODAY ANNOUNCED THE APPOINTMENT OF SCOTT GARLAND TO ITS BOARD OF DIRECTORS AND THE PLANNED RESIGNATION OF ANDREW PHILLIPS, PH.D.

ENLIVEN THERAPEUTICS BOLSTERS BOARD TO PREPARE FOR NEXT PHASE OF DEVELOPMENT

BOULDER,COLO., DEC. 11, 2025 /PRNEWSWIRE/ -- ENLIVEN THERAPEUTICS, INC. ("ENLIVEN"), (NASDAQ: ELVN), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF SMALL MOLECULE THERAPEUTICS, TODAY ANNOUNCED THAT ON DECEMBER 11, 2025, ENLIVEN GRANTED AN INDUCEMENT STOCK OPTION TO PURCHASE 875,000 SHARES OF ENLIVEN'S COMMON STOCK TO RICHARD FAIR, ENLIVEN'S PRESIDENT AND CHIEF EXECUTIVE OFFICER AND MEMBER OF THE BOARD OF DIRECTORS, IN CONNECTION WITH THE COMMENCEMENT OF RICHARD FAIR'S EMPLOYMENT.

ENLIVEN THERAPEUTICS REPORTS INDUCEMENT GRANTS AS PERMITTED BY THE NASDAQ LISTING RULES

RICK FAIR, A SEASONED EXECUTIVE WITH DEEP EXPERIENCE DEVELOPING AND COMMERCIALIZING HEMATOLOGY PRODUCTS, JOINS ENLIVEN AS CHIEF EXECUTIVE OFFICER CO-FOUNDER SAM KINTZ WILL ASSUME A NEW POSITION AS HEAD OF PIPELINE BOULDER, COLO. , DEC. 11, 2025 /PRNEWSWIRE/ -- ENLIVEN THERAPEUTICS, INC. (ENLIVEN OR THE COMPANY) (NASDAQ: ELVN), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF SMALL MOLECULE THERAPEUTICS, TODAY ANNOUNCED THE APPOINTMENT OF RICK FAIR AS CHIEF EXECUTIVE OFFICER AND MEMBER OF THE BOARD OF DIRECTORS OF ENLIVEN, EFFECTIVE DECEMBER 11, 2025.

ENLIVEN THERAPEUTICS ANNOUNCES NEW CEO TO DRIVE NEXT PHASE OF DEVELOPMENT

COMPLETED ENROLLMENT OF THE RANDOMIZED PHASE 1B COHORTS OF THE ONGOING ENABLE TRIAL OF ELVN-001 IN CML REMAINS ON TRACK TO INITIATE PHASE 3 PIVOTAL TRIAL OF ELVN-001 IN 2026 STRONG BALANCE SHEET WITH $478 MILLION IN CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES, WHICH IS EXPECTED TO PROVIDE CASH RUNWAY INTO THE FIRST HALF OF 2029 BOULDER, COLO. , NOV. 12, 2025 /PRNEWSWIRE/ -- ENLIVEN THERAPEUTICS, INC. (ENLIVEN OR THE COMPANY) (NASDAQ: ELVN), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF SMALL MOLECULE THERAPEUTICS, TODAY REPORTED FINANCIAL RESULTS FOR THE THIRD QUARTER ENDEDSEPTEMBER 30, 2025, AND PROVIDED A BUSINESS UPDATE, INCLUDING HIGHLIGHTS OF PIPELINE PROGRESS.

ENLIVEN THERAPEUTICS REPORTS THIRD QUARTER FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE

BOULDER, COLO. , AUG. 25, 2025 /PRNEWSWIRE/ --ENLIVEN THERAPEUTICS, INC. (ENLIVEN OR THE COMPANY) (NASDAQ: ELVN), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF SMALL MOLECULE THERAPEUTICS, TODAY ANNOUNCED THE COMPANY WILL PRESENT DATA FROM ITS ENABLE PHASE 1A/1B CLINICAL TRIAL OF ELVN-001 IN BOTH AN ORAL AND A POSTER PRESENTATION AT THE SOCIETY OF HEMATOLOGIC ONCOLOGY (SOHO) 2025 ANNUAL MEETING, TAKING PLACE SEPTEMBER 3-6, 2025, AT THE GEORGE R.

ENLIVEN THERAPEUTICS ANNOUNCES ORAL AND POSTER PRESENTATIONS AT THE SOCIETY OF HEMATOLOGIC ONCOLOGY (SOHO) 2025 ANNUAL MEETING

ANNOUNCED POSITIVE DATA FROM THE PHASE 1 CLINICAL TRIAL OF ELVN-001 IN CML, REPORTING A CUMULATIVE MMR RATE OF 47% WITH 32% OF PATIENTS ACHIEVING MMR BY 24 WEEKS AND DEMONSTRATING A FAVORABLE SAFETY AND TOLERABILITY PROFILE ACROSS ALL DOSE LEVELS STRONG BALANCE SHEET WITH $ 491 MILLION IN CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES, WHICH IS EXPECTED TO PROVIDE CASH RUNWAY INTO THE FIRST HALF OF 2029 BOULDER, COLO. , AUG. 13, 2025 /PRNEWSWIRE/ -- ENLIVEN THERAPEUTICS, INC. (ENLIVEN OR THE COMPANY) (NASDAQ: ELVN), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF SMALL MOLECULE THERAPEUTICS, TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025, AND PROVIDED A BUSINESS UPDATE, INCLUDING HIGHLIGHTS OF PIPELINE PROGRESS.

ENLIVEN THERAPEUTICS REPORTS SECOND QUARTER FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE

BOULDER, COLO. , JUNE 16, 2025 /PRNEWSWIRE/ -- ENLIVEN THERAPEUTICS, INC. (ENLIVEN OR THE COMPANY) (NASDAQ: ELVN), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF SMALL MOLECULE THERAPEUTICS, TODAY ANNOUNCED THAT IT HAS CLOSED ITS UNDERWRITTEN PUBLIC OFFERING OF 9,920,987 SHARES OF ITS COMMON STOCK, WHICH INCLUDES THE FULL EXERCISE OF THE UNDERWRITERS' OPTION TO PURCHASE 1,526,250 ADDITIONAL SHARES OF ITS COMMON STOCK, AT A PRICE TO THE PUBLIC OF $19.66 PER SHARE AND, IN LIEU OF COMMON STOCK TO CERTAIN INVESTORS, PRE-FUNDED WARRANTS TO PURCHASE 1,780,263 SHARES OF ITS COMMON STOCK AT A PRICE TO THE PUBLIC OF $19.659 PER PRE-FUNDED WARRANT, WHICH REPRESENTS THE PER SHARE PUBLIC OFFERING PRICE OF EACH SHARE OF ENLIVEN'S COMMON STOCK LESS THE $0.001 PER SHARE EXERCISE PRICE FOR EACH PRE-FUNDED WARRANT.

ENLIVEN THERAPEUTICS ANNOUNCES CLOSING OF PUBLIC OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS AND FULL EXERCISE OF THE UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES

BOULDER, COLO. , JUNE 13, 2025 /PRNEWSWIRE/ -- ENLIVEN THERAPEUTICS, INC. (ENLIVEN OR THE COMPANY) (NASDAQ: ELVN), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF SMALL MOLECULE THERAPEUTICS, TODAY ANNOUNCED THAT IT HAS PRICED ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN PUBLIC OFFERING OF 8,394,737 SHARES OF ITS COMMON STOCK AT A PRICE TO THE PUBLIC OF $19.66 PER SHARE AND, IN LIEU OF COMMON STOCK TO INVESTORS WHO SO CHOOSE, PRE-FUNDED WARRANTS TO PURCHASE UP TO 1,780,263 SHARES OF ENLIVEN'S COMMON STOCK AT A PRICE TO THE PUBLIC OF $19.659 PER PRE-FUNDED WARRANT, WHICH REPRESENTS THE PER SHARE PUBLIC OFFERING PRICE OF EACH SHARE OF ENLIVEN'S COMMON STOCK LESS THE $0.001 PER SHARE EXERCISE PRICE FOR EACH PRE-FUNDED WARRANT.

ENLIVEN THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS

BOULDER, COLO. , JUNE13, 2025 /PRNEWSWIRE/ -- ENLIVEN THERAPEUTICS, INC. (ENLIVEN OR THE COMPANY) (NASDAQ: ELVN), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF SMALL MOLECULE THERAPEUTICS, TODAY ANNOUNCED THAT IT HAS COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF $200 MILLION OF SHARES OF ITS COMMON STOCK AND, IN LIEU OF COMMON STOCK TO INVESTORS WHO SO CHOOSE, PRE-FUNDED WARRANTS TO PURCHASE SHARES OF ENLIVEN'S COMMON STOCK.

Enliven Therapeutics, Inc.

ELVN

Price

Financial Reports

No items found.

Press Releases

Enliven Therapeutics, Inc.

ELVN.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

ELVN